Skip to main content

Table 1 Cell line specifications

From: MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index

Cell line Seeding concentration Rituximab Cyclophosphamide Doxorubicin Vincristine ABC/GCB
  cells/mL AUC   AUC   AUC   AUC   
DB 0.125 × 106 318.1 Int 345.6 Res 275.5 Res 130.7 Res GCB
FARAGE 0.25 × 106 344.1 Int 311.0 Res 179.6 Sen 56.1 Sen GCB
HBL-1 0.25 × 106 421.9 Res 226.0 Int 272.2 Int 84.5 Int ABC
MC-116 0.25 × 106 NA NA NA NA 271.8 Int 62.0 NA* GCB
NU-DHL-1 0.125 × 106 316.6 Int 171.7 Sen 200.6 Sen NA NA ABC
NU-DUL-1 0.25 × 106 236.4 Sen 214.1 Sen 223.9 Int 90.3 Int UC
OCI-Ly3 0.125 × 106 407.6 Res 261.7 Int 253.4 Int 74.8 Int ABC
OCI-Ly7 0.125 × 106 218.3 Res 257.9 Sen 324.9 Res 114.5 Int GCB
OCI-Ly8 0.25 × 106 406.6 Res NA NA NA NA NA NA UC
OCI-Ly19 0.25 × 106 400.4 Res 202.1 Sen 166.9 Sen 54.0 Sen UC
RIVA 0.25 × 106 275.8 Res 296.0 Int 326.7 Res 109.0 Res ABC
SU-DHL-4 0.25 × 106 150.4 Sen NA NA 288.8 Res NA NA GCB
SU-DHL-5 0.25 × 106 251.2 Sen 164.5 Sen 201.5 Sen 57.9 Sen GCB
SU-DHL-8 0.5 × 106 425.0 Res 270.6 Int 222.0 Sen 126.1 Res GCB
U2932 0.4 × 106 354.1 Int 329.8 Res 294.8 Res 85.3 Int GCB
  1. For each drug, DLBCL cell lines were ranked according to sensitivity based on area under the dose-response curve (AUC) for rituximab, cyclophosphamide, doxorubicin, and vincristine. Division into tertiles defines: Rituximab, 4 sensitive, 5 intermediate, 5 resistant; Cyclophosphamide, 4 sensitive, 4 intermediate, 4 resistant; Doxorubicin, 5 sensitive, 4 intermediate, 5 resistant; Vincristine, 4 sensitive, 4 intermediate, 4 resistant. Based on GEP, DLBCL cell lines were classified into ABC/GCB subclasses by Wright classification using published algorithms at hemaClass.org [17]. ABC, activated B-cell like; GCB, germinal center B-cell like; Int, intermediate; NA, not available; Res, resistant; Sen, sensitive; * excluded due to large variation between replicates